Core Viewpoint - The company has approved the 2025 equity incentive plan and the list of initial grant recipients, ensuring compliance with relevant regulations and internal procedures [1][2][3] Group 1: Public Disclosure and Verification - The company publicly disclosed the names and positions of the initial grant recipients from June 27 to July 7, 2025, allowing for a feedback period of at least 10 days [1][2] - During the public disclosure period, the supervisory board received no objections regarding the incentive plan recipients [2] - The supervisory board verified the eligibility of the initial grant recipients based on their employment contracts and positions within the company [2] Group 2: Supervisory Board's Review Opinion - The supervisory board confirmed that the individuals included in the initial grant recipient list meet the conditions set forth by the Company Law and relevant regulations [2][3] - The initial grant recipients do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares [2] - The basic information of the initial grant recipients is accurate, with no instances of falsehood or significant misrepresentation [3]

Group 1 - The company is proposing a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][6][8] - The stock option incentive plan has been approved by the company's board and supervisory committee and is now submitted for shareholder approval [6][8] - The company will conduct the shareholder meeting on July 14, 2025, with both on-site and online voting options available [5][7] Group 2 - The company plans to change its name from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." to enhance group management and resource utilization [12][13] - The name change aligns with the company's strategic development needs and will not adversely affect its operations or shareholder interests [13][14] - The company will also revise its articles of association to reflect the name change and will seek necessary approvals for the changes [14][22] Group 3 - The company intends to adjust its fundraising investment projects, specifically changing the focus from "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" [16][19] - The total amount of funds to be redirected is approximately 84.37 million yuan, which will be fully allocated to the new project [15][19] - The integrase inhibitor project aims to develop a new generation of anti-HIV drugs and has shown promising results in initial clinical trials [20][21] Group 4 - The company is proposing the appointment of a new independent director candidate, Hu Wenyuan, following the resignation of the previous independent director [11][12] - The nomination has been approved by the board and is now subject to shareholder approval [11][12] - The company is also seeking to fill a vacancy in the supervisory board due to the resignation of a non-employee representative supervisor [22][23]

Core Viewpoint - Beijing Orient Telecom Technology Co., Ltd. has terminated its 2025 stock option incentive plan and canceled all unexercised stock options due to the inability to continue the plan following negative audit reports [1][2]. Group 1: Termination of Stock Option Plan - The company held meetings on June 6, 2025, where the board and supervisory committee approved the termination of the 2025 stock option incentive plan and the cancellation of stock options [1]. - The decision was influenced by the audit report from Beijing Dehao International Accounting Firm, which issued an inability to express an opinion for the 2024 annual audit and a negative opinion on the internal control audit [1]. Group 2: Details of Stock Option Cancellation - A total of 12 million stock options granted to 130 individuals will be canceled, along with the termination of related documents such as the assessment management measures for the incentive plan [1]. - The cancellation of the unexercised stock options will not affect the company's capital structure [2].

Core Viewpoint - The legal opinion letter from Shanghai Junlan Law Firm addresses the cancellation of stock options and the repurchase of restricted stocks by Milkway Intelligent Supply Chain Service Group Co., Ltd, confirming that the actions comply with relevant regulations and will not materially affect the company's financial status or operational results [1][22][23]. Summary by Sections Approval and Authorization of Cancellation - The cancellation of stock options and repurchase of restricted stocks has been approved and authorized by the company's board, in accordance with the relevant incentive plans and regulations [4][9][22]. Details of Cancellation - For the 2021 incentive plan, a total of 1,981,400 stock options will be canceled due to non-exercise by the eligible participants within the specified periods [9][10][12]. - The 2022 incentive plan will see the cancellation of 56,000 stock options, also due to non-exercise by the eligible participants [16][18]. - The 2024 incentive plan will result in the cancellation of 633,682 stock options, primarily due to the departure of eligible employees and unmet performance targets [19][21]. Financial Impact - The cancellation of stock options and repurchase of restricted stocks is not expected to have a substantial impact on the company's financial condition or operational results [15][22][23]. Information Disclosure - The company is required to disclose relevant information regarding the cancellations and repurchases in accordance with applicable laws and regulations [23][24].

Group 1 - The legal opinion letter is issued by Beijing Global Law Firm Shanghai Branch regarding Qingdao Pangu Intelligent Manufacturing Co., Ltd.'s 2023 Restricted Stock Incentive Plan [1][4] - The plan was approved during the fourth extraordinary general meeting of shareholders on December 18, 2023, allowing the board to implement the plan [4][5] - The initial grant date for the restricted stock is set for December 18, 2023, with a grant price of 16.90 yuan per share for 550,000 shares to 72 eligible participants [5][6] Group 2 - On April 21, 2025, the board approved an adjustment of the grant price from 16.70 yuan to 16.565 yuan per share and invalidated 569,600 shares that were granted but not vested [6][7] - The adjustment of the grant price is in accordance with the provisions of the incentive plan, which allows for price adjustments due to capital increases, stock dividends, or other corporate actions [7][9] - The adjusted grant price after a cash dividend of 2.00 yuan per share is calculated to be 16.365 yuan per share [9][10] Group 3 - The legal opinion concludes that the price adjustment has received the necessary approvals and complies with relevant regulations, and the company must fulfill its information disclosure obligations [10]

Core Viewpoint - The legal opinion letter confirms that Shanghai Fuhuan Microelectronics Co., Ltd. has obtained the necessary approvals and authorizations for adjusting the stock option exercise prices in its 2021 and 2022 incentive plans, in compliance with relevant regulations and company articles [1][10]. Group 1: Approval and Authorization - The adjustments for the 2021 incentive plan have received necessary approvals and authorizations from the company's shareholders, allowing the board to adjust the stock option exercise price in case of dividend distributions [5][6]. - The adjustments for the 2022 incentive plan have also been authorized by the shareholders, permitting the board to make similar adjustments as per the plan's provisions [6][7]. Group 2: Reasons for Adjustment - The adjustments are necessitated by the company's capital actions, such as stock dividends or other corporate actions that require a corresponding adjustment to the stock option exercise prices as outlined in both incentive plans [7][8]. Group 3: Adjustment Method and Results - The adjustment method involves calculating the new exercise price by deducting the dividend amount from the previous exercise price, ensuring that the adjusted price remains above 1 [8][9]. - The specific adjustments include a reduction in the exercise price for the 2021 plan from 42.93 CNY/share to 42.81 CNY/share and for the 2022 plan from 64.92 CNY/share to 64.80 CNY/share [9][10].

Core Viewpoint - The company has completed the second unlock period of its 2022 restricted stock incentive plan, allowing 510 eligible participants to unlock a total of 4.545 million shares, which will be listed for trading on July 9, 2025 [1][13]. Summary by Sections Incentive Plan Approval and Disclosure - The company held board and supervisory meetings to approve the 2022 restricted stock incentive plan and its related management measures [1][3]. - The plan was filed with the Chengdu State-owned Assets Supervision and Administration Commission, which provided a principle agreement for the plan [2]. Unlock Conditions and Compliance - The second unlock period has been reached, with the conditions for unlocking met, including no significant objections from supervisory bodies and compliance with financial reporting standards [6][9]. - The company maintained a sound governance structure and met performance assessment requirements, including a minimum earnings per share of 0.5884 yuan and revenue of at least 8 billion yuan for 2023 [9][10]. Unlock Details - A total of 4.545 million shares will be unlocked, representing approximately 0.1523% of the company's total share capital [14]. - The number of eligible participants for this unlock is 510, with the total number of restricted shares granted being 1,515 million [14][15]. Changes in Share Structure - Following the unlock, the structure of the company's shares will change, with the number of restricted shares decreasing from 9,636,500 to 5,091,500, while unrestricted shares will increase accordingly [17]. Documentation and Legal Compliance - The company has prepared various documents for review, including board resolutions and legal opinions, to ensure compliance with regulations [18].

证券代码：688608 证券简称：恒玄科技 公告编号：2025-036 恒玄科技（上海）股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 恒玄科技（上海）股份有限公司（以下简称"公司"）第二届监事会第十八次 会议通知于 2025 年 6 月 30 日送达全体监事，会议于 2025 年 7 月 7 日以现场方 式召开，应出席会议的监事 3 人，实际出席监事 3 人。本次会议由监事会主席黄 律拯女士主持。会议的召集与召开程序符合《中华人民共和国公司法》和《恒玄 科技（上海）股份有限公司公司章程》等相关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 本次会议由监事会主席黄律拯女士主持，经全体监事表决，形成决议如下： 《上市公司股权激 励管理办法》等法律、法规和规范性文件中关于激励计划调整的相关规定，履行 了必要的程序。本次调整在公司股东大会授权范围内，调整的程序合法合规，不 存在损害公司及股东利益的情形。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在上 ...

上海市锦天城律师事务所关于 恒玄科技（上海）股份有限公司 首次授予部分第三个归属期符合归属条件 及部分已授予尚未归属的限制性股票作废事项之 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所关于 恒玄科技（上海）股份有限公司 首次授予部分第三个归属期符合归属条件 及部分已授予尚未归属的限制性股票作废事项之 法律意见书 致：恒玄科技（上海）股份有限公司 华人民共和国证券法》 《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科 创板上市公司自律监管指南第 4 号——股权激励信息披露》（以下简称《监管指 南第 4 号》）及其他有关法律、法规、规范性文件及《恒玄科技（上海）股份有 限公司章程》的规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神， 为恒玄科技拟实施 2022 年限制性股票激励计划（以下简称"2022 年限制性股票 激励计划"）调整、2023 年 ...

Core Viewpoint - The legal opinion letter issued by Beijing Jindu Law Firm Shanghai Branch confirms that Shanghai Jin Jiang International Hotel Co., Ltd. has obtained the necessary approvals and authorizations for the repurchase and cancellation of part of the restricted stock under the 2024 Restricted Stock Incentive Plan, in compliance with relevant laws and regulations [1][12]. Group 1: Approval and Authorization - The company has obtained necessary approvals from the board of directors and the supervisory board regarding the repurchase and cancellation of 2,625,259 shares of restricted stock due to performance assessment failures and employee departures [6][12]. - The repurchase and cancellation process is in accordance with the provisions of the 2024 Restricted Stock Incentive Plan and the relevant regulations [5][12]. Group 2: Repurchase Details - The repurchase is triggered by the failure to meet performance assessment criteria, with the repurchase price set at the lower of the grant price (11.85 yuan/share) or the market price prior to the board meeting [7][9]. - The company plans to use its own funds for the repurchase of the restricted stock [10]. Group 3: Information Disclosure and Implementation - The company has disclosed the repurchase and cancellation details through announcements on the Shanghai Stock Exchange and has notified creditors accordingly [10]. - The repurchase is scheduled to be completed by July 10, 2025, following the necessary procedures for capital reduction and share cancellation registration [10][12].